Ovid Therapeutics (OVID) Non-Current Assets (2016 - 2026)

Ovid Therapeutics (OVID) has reported Non-Current Assets for 11 consecutive years, with $108.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 206.62% year-over-year to $108.4 million; the trailing twelve-month figure through Jun 2026 stood at $285.4 million (up 98.04% YoY), and the FY2025 full-year result was $76.6 million, up 111.35% from the prior year.
• Non-Current Assets climbed to $108.4 million in Q2 2026 per OVID's latest filing, from $65.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $108.4 million in Q2 2026 and bottomed at $21.0 million in Q1 2022.
• Historically, Non-Current Assets has averaged $40.1 million across 5 years, with a median of $35.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 2546.02% in 2022, then declined 7.05% in 2025.
• Over 5 years, Non-Current Assets stood at $23.9 million in 2022, then surged by 44.14% to $34.4 million in 2023, then grew by 5.22% to $36.2 million in 2024, then jumped by 111.35% to $76.6 million in 2025, then surged by 41.52% to $108.4 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $108.4 million, $65.5 million, and $76.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.